论文部分内容阅读
[目的]观察康复新口服液联合三联疗法治疗儿童幽门螺杆菌(Hp)阳性相关性慢性胃炎(CG)的临床疗效。[方法]将胃镜确诊的85例13C尿素呼气试验(13C-UBT)及血清Hp-IgG测定Hp均阳性的CG患儿随机分2组,对照组42例,予克拉霉素加阿莫西林加蒙脱石散治疗;治疗组43例在此基础上加服康复新液5~10 ml/次,3次/d,均连服2周。疗程结束后4周,复查胃镜并检测Hp。[结果]2组治疗后各症状积分及总积分均显著低于治疗前(P<0.01),2组治疗后比较P<0.05。胃黏膜炎症愈合率治疗组93.1%,对照组64.0%(P<0.01),总有效率分别为97.7%和92.8%;Hp清除率对照组93.5%,治疗组90.7%(P>0.05)。[结论]康复新液联合三联疗法治疗儿童Hp相关性CG疗效优于单纯三联疗法。
[Objective] To observe the clinical effect of Kang Fu Xin Oral Liquid combined with triple therapy in the treatment of Helicobacter pylori (Hp) -positive chronic gastritis (CG) in children. [Methods] 85 CG patients diagnosed by gastroscopy (13C-UBT) and Hp-IgG positive Hp-positive CG children were randomly divided into two groups, the control group, 42 cases, to clarithromycin plus amoxicillin Plus montmorillonite scattered treatment; treatment group on the basis of 43 cases with rehabilitation rehabilitation fluid 5 ~ 10 ml / time, 3 times / d, even for 2 weeks. Four weeks after the end of treatment, gastroscopy was performed and Hp was examined. [Results] The score of each symptom and the total score of the two groups after treatment were significantly lower than those before treatment (P <0.01), and those of the two groups after treatment were P <0.05. The healing rate of gastric mucosal inflammation was 93.1% in the treatment group and 64.0% in the control group (P <0.01). The total effective rates were 97.7% and 92.8% respectively. The Hp clearance rate was 93.5% in the control group and 90.7% in the treatment group (P> 0.05). [Conclusion] Kangfuxin combined with triple therapy is superior to triple therapy in treating Hp-related CG in children.